Does Mounjaro Cause UTIs?
Mounjaro (tirzepatide) does not directly cause urinary tract infections (UTIs), as this is not a recognized adverse effect of this medication class (GLP-1/GIP receptor agonists). The FDA prescribing information for Mounjaro does not list UTIs among its adverse reactions or warnings 1.
Key Distinction from SGLT2 Inhibitors
It's critical to distinguish tirzepatide from SGLT2 inhibitors (like empagliflozin, dapagliflozin, canagliflozin), which do cause genitourinary infections including UTIs at rates of 2-10%, particularly in females 2. This confusion likely arises because both drug classes are used in type 2 diabetes management, but they have entirely different mechanisms of action:
- SGLT2 inhibitors increase urinary glucose excretion, creating a glucose-rich environment in the urinary tract that promotes bacterial and fungal growth
- Tirzepatide works through incretin receptor activation and does not cause glucosuria
Mounjaro's Actual Adverse Effect Profile
The most common adverse reactions with Mounjaro (occurring in ≥5% of patients) are 1:
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Dyspepsia
- Abdominal pain
Renal Safety Data
Recent meta-analysis of 15 RCTs (n=14,471) with low risk of bias demonstrated that tirzepatide has a reassuring renal safety profile and did not increase risks of urinary tract infections compared to placebo, insulin, or other GLP-1 receptor agonists 3. The medication actually showed beneficial effects on albuminuria without detrimental effects on kidney function.
Clinical Caveat
While tirzepatide doesn't cause UTIs, the gastrointestinal side effects (nausea, vomiting, diarrhea) can lead to dehydration, which theoretically could increase UTI susceptibility through reduced urinary flow. However, this is an indirect effect related to volume depletion, not a direct drug effect 1. Monitor hydration status, especially during dose escalation.